Role of Interleukin 33 in Immune Response Process of Vitiligo Disease | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 149, Volume 85, Issue 1, October 2021, Page 3483-3486 PDF (510.46 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2021.199720 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mariam Nasr Gado  ; Marwa Mohamed Fathi; Naglaa Ali Khalifa; Sahar Mohamed Al-Mokadem; Ibrahim El-Gharib El- Ganiny
| ||||
| Abstract | ||||
| Background: When melanocytes cease to operate, vitiligo develops. It is a skin and mucosa depigmentation condition. Any area of the body can develop well-circumscribed white macules or patches in this disease. Approximately 1-2 percent of the population is affected by Vitiligo. Suppression of tumorigenicity 2 (ST2), a newly discovered member of the interleukin-1 (IL-1) family, acts as a receptor for the IL-1 receptor-like 1 protein (also known as IL-1RL1) while also acting as a ligand for the interleukin-1 receptor-like 1 protein (also known as IL-1RL1) and suppressing tumorigenicity 2. Objective: To study Interleukin 33 (IL-33) in generalized and localized vitiligo patients and to assess their relationship with disease activity. Conclusion: Vitiligo could be associated with increased serum levels of IL-33, which could help as predictor marker of disease activity in vitiligo. | ||||
| Keywords | ||||
| Vitiligo; Interleukin 33 (IL-33) | ||||
|
Statistics Article View: 283 PDF Download: 462 |
||||
